Carisma Therapeutics (NASDAQ:CARM) Given In-Line Rating at Evercore ISI

Evercore ISI restated their in-line rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a report issued on Wednesday,Benzinga reports. The firm currently has a $0.70 price target on the stock, down from their previous price target of $4.00.

Other analysts also recently issued reports about the company. D. Boral Capital decreased their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a report on Monday. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, HC Wainwright cut their price objective on shares of Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, November 25th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Carisma Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $4.94.

Carisma Therapeutics Stock Performance

Shares of Carisma Therapeutics stock opened at $0.56 on Wednesday. The business has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $1.05. The company has a market cap of $23.23 million, a PE ratio of -0.36 and a beta of 1.44. Carisma Therapeutics has a one year low of $0.56 and a one year high of $3.16. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. On average, equities research analysts forecast that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after buying an additional 11,200 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Carisma Therapeutics in the 2nd quarter valued at $40,000. Wexford Capital LP boosted its stake in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Finally, Barclays PLC grew its position in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.